KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Change in Account Payables (2020 - 2025)

Historic Change in Account Payables for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to -$5.9 million.

  • Recursion Pharmaceuticals' Change in Account Payables fell 28929.28% to -$5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year increase of 15424.15%. This contributed to the annual value of $6.4 million for FY2024, which is 75197.57% up from last year.
  • Latest data reveals that Recursion Pharmaceuticals reported Change in Account Payables of -$5.9 million as of Q3 2025, which was down 28929.28% from -$4.8 million recorded in Q2 2025.
  • Recursion Pharmaceuticals' 5-year Change in Account Payables high stood at $8.1 million for Q4 2024, and its period low was -$5.9 million during Q3 2025.
  • Over the past 5 years, Recursion Pharmaceuticals' median Change in Account Payables value was $71000.0 (recorded in 2021), while the average stood at $101315.8.
  • In the last 5 years, Recursion Pharmaceuticals' Change in Account Payables skyrocketed by 579090.91% in 2021 and then tumbled by 148873.24% in 2022.
  • Recursion Pharmaceuticals' Change in Account Payables (Quarter) stood at -$3.5 million in 2021, then surged by 119.82% to $695000.0 in 2022, then crashed by 145.61% to -$317000.0 in 2023, then skyrocketed by 2662.15% to $8.1 million in 2024, then plummeted by 172.52% to -$5.9 million in 2025.
  • Its Change in Account Payables was -$5.9 million in Q3 2025, compared to -$4.8 million in Q2 2025 and $3.7 million in Q1 2025.